ATE375793T1 - Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen - Google Patents

Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen

Info

Publication number
ATE375793T1
ATE375793T1 AT04021728T AT04021728T ATE375793T1 AT E375793 T1 ATE375793 T1 AT E375793T1 AT 04021728 T AT04021728 T AT 04021728T AT 04021728 T AT04021728 T AT 04021728T AT E375793 T1 ATE375793 T1 AT E375793T1
Authority
AT
Austria
Prior art keywords
lower alkyl
aryl
heterocyclic
unsubstituted
substituted
Prior art date
Application number
AT04021728T
Other languages
English (en)
Inventor
Robert H Harris
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of ATE375793T1 publication Critical patent/ATE375793T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
AT04021728T 2000-08-25 2001-08-24 Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen ATE375793T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22823000P 2000-08-25 2000-08-25

Publications (1)

Publication Number Publication Date
ATE375793T1 true ATE375793T1 (de) 2007-11-15

Family

ID=22856332

Family Applications (4)

Application Number Title Priority Date Filing Date
AT01966230T ATE357227T1 (de) 2000-08-25 2001-08-24 Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz
AT06012400T ATE476971T1 (de) 2000-08-25 2001-08-24 Aminosäure enthaltende antikonvulsiva zur behandlung von zwangsstörungen
AT04021727T ATE375792T1 (de) 2000-08-25 2001-08-24 Verwendung von antikonvulsiven aminosäure zur behandlung von migräne
AT04021728T ATE375793T1 (de) 2000-08-25 2001-08-24 Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen

Family Applications Before (3)

Application Number Title Priority Date Filing Date
AT01966230T ATE357227T1 (de) 2000-08-25 2001-08-24 Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz
AT06012400T ATE476971T1 (de) 2000-08-25 2001-08-24 Aminosäure enthaltende antikonvulsiva zur behandlung von zwangsstörungen
AT04021727T ATE375792T1 (de) 2000-08-25 2001-08-24 Verwendung von antikonvulsiven aminosäure zur behandlung von migräne

Country Status (13)

Country Link
US (6) US6884910B2 (de)
EP (5) EP1486205B1 (de)
JP (2) JP4307068B2 (de)
AT (4) ATE357227T1 (de)
AU (6) AU8676301A (de)
CA (2) CA2740815C (de)
CY (5) CY1107668T1 (de)
DE (4) DE60142806D1 (de)
DK (4) DK1486205T3 (de)
ES (5) ES2348646T3 (de)
LU (1) LU91512I2 (de)
PT (4) PT1486205E (de)
WO (1) WO2002015922A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE357227T1 (de) 2000-08-25 2007-04-15 Res Corp Technologies Inc Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
DE60100055T2 (de) * 2001-03-21 2003-07-24 Sanol Arznei Schwarz Gmbh Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US20050233472A1 (en) * 2003-09-19 2005-10-20 Kao H P Spotting high density plate using a banded format
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
EP1537862A1 (de) * 2003-12-02 2005-06-08 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von zentralen neuropathische-Schmerzen
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
CA2562937A1 (en) * 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (de) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604655A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1629839A1 (de) * 2004-08-27 2006-03-01 Schwarz Pharma Ag Verwendung von Peptidverbindungen zur Behandlung von Knochenkrebsschmerz sowie von Chemotherapie- oder Nukleosid-induziertem Schmerz
AU2005276634B2 (en) * 2004-08-27 2011-03-24 Ucb Pharma Gmbh Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EA027836B1 (ru) 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
EP1920780A1 (de) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptidverbindungen zur Behandlung von Krankheiten mit erhöhter Erregbarkeit
US7489198B1 (en) 2007-04-26 2009-02-10 Lockheed Martin Corporation Linear regulating switch
WO2011101863A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
AU2015280108B2 (en) * 2014-06-23 2019-11-28 Naurex, Inc. Methods of treating or ameliorating migraine
KR20180064535A (ko) 2015-11-03 2018-06-14 킴벌리-클라크 월드와이드, 인크. 고 벌크 및 저 린트를 갖는 페이퍼 티슈
US11255051B2 (en) 2017-11-29 2022-02-22 Kimberly-Clark Worldwide, Inc. Fibrous sheet with improved properties
GB2590316B (en) 2018-07-25 2022-06-01 Kimberly Clark Co Process for making three-dimensional foam-laid nonwovens

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795788A (nl) * 1972-02-22 1973-08-22 Akzo Nv Werkwijze ter bereiding van peptiden en peptide-derivaten en de toepassing hiervan
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
FR2546517B1 (fr) * 1983-05-24 1987-04-24 Panmedica Nouveaux dipeptides du -l-5-hydroxy-tryptophane, procedes pour leur preparation et medicaments les contenant
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5331089A (en) * 1988-03-25 1994-07-19 Merck Sharpe & Dohme, Ltd. Peptides useful as tachykinin agonists
US5178729A (en) * 1991-01-15 1993-01-12 James River Corporation Of Virginia High purity stratified tissue and method of making same
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
WO1994017794A1 (en) 1993-02-03 1994-08-18 Steven Andrew Jennings Blends of glycine derivatives and sugars
DE59409631D1 (de) * 1993-07-15 2001-02-15 Hoffmann La Roche Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
US6348571B1 (en) * 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
WO1996011209A1 (en) * 1994-10-05 1996-04-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
KR100522012B1 (ko) 1997-07-08 2005-10-18 오노 야꾸힝 고교 가부시키가이샤 아미노산 유도체
WO1999002146A1 (fr) 1997-07-08 1999-01-21 Ono Pharmaceutical Co., Ltd. Derives d'acide amine
AU744899B2 (en) 1997-07-15 2002-03-07 Research Corporation Technologies, Inc. Amino acid derivatives useful to treat stroke
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders
EP1084704B1 (de) 1998-06-10 2006-03-29 Meiji Seika Kaisha Ltd. Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6399574B1 (en) * 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
ATE357227T1 (de) 2000-08-25 2007-04-15 Res Corp Technologies Inc Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz
US6228825B1 (en) 2000-10-13 2001-05-08 Colgate Palmolive Company Automatic dishwashing cleaning system
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter

Also Published As

Publication number Publication date
CY1107668T1 (el) 2010-07-28
EP1695703A3 (de) 2006-12-13
CA2740815A1 (en) 2002-02-28
ES2435000T3 (es) 2013-12-18
DE60127459D1 (de) 2007-05-03
JP2009108090A (ja) 2009-05-21
DE60127459T2 (de) 2007-07-12
DK1486205T3 (da) 2008-02-18
CA2419285A1 (en) 2002-02-28
CY2009002I2 (el) 2009-11-04
US20040087508A1 (en) 2004-05-06
EP1365787A2 (de) 2003-12-03
JP4307068B2 (ja) 2009-08-05
AU2009202362B2 (en) 2011-01-27
AU2007202336B2 (en) 2009-09-24
DE60142806D1 (de) 2010-09-23
EP1365787B1 (de) 2007-03-21
AU2007202336B9 (en) 2009-10-29
CY1107852T1 (el) 2013-06-19
CY2009002I1 (el) 2009-11-04
PT1365787E (pt) 2007-06-29
US8519183B2 (en) 2013-08-27
AU2001286763C1 (en) 2006-03-02
ES2294414T3 (es) 2008-04-01
CY1112349T1 (el) 2015-12-09
DE60131032D1 (de) 2007-11-29
AU2001286763B2 (en) 2005-11-24
EP1695703B1 (de) 2010-08-11
US6884910B2 (en) 2005-04-26
ATE476971T1 (de) 2010-08-15
EP2210598B1 (de) 2013-09-18
DE60131032T2 (de) 2008-08-14
ATE375792T1 (de) 2007-11-15
DK1486206T3 (da) 2008-02-11
DE60131033T2 (de) 2008-07-17
US20070142297A1 (en) 2007-06-21
US20100273716A1 (en) 2010-10-28
ES2348646T3 (es) 2010-12-10
US20130316953A1 (en) 2013-11-28
AU2009202363A1 (en) 2009-07-02
EP1486205B1 (de) 2007-10-17
PT1486205E (pt) 2008-01-25
PT1695703E (pt) 2010-11-16
US20040097416A1 (en) 2004-05-20
EP2210598A2 (de) 2010-07-28
CY1107853T1 (el) 2013-06-19
DK1365787T3 (da) 2007-07-23
AU2009202363B2 (en) 2011-02-17
JP5190334B2 (ja) 2013-04-24
US7772427B2 (en) 2010-08-10
ES2281439T3 (es) 2007-10-01
US7148378B2 (en) 2006-12-12
CA2740815C (en) 2014-03-18
EP1486205A1 (de) 2004-12-15
ES2294415T3 (es) 2008-04-01
AU2009202362A1 (en) 2009-07-02
US7186859B2 (en) 2007-03-06
AU2011202293A1 (en) 2011-06-09
EP1486206A1 (de) 2004-12-15
WO2002015922A2 (en) 2002-02-28
ATE357227T1 (de) 2007-04-15
WO2002015922A3 (en) 2003-09-25
AU8676301A (en) 2002-03-04
DK1695703T3 (da) 2010-10-25
EP1695703A2 (de) 2006-08-30
JP2004506692A (ja) 2004-03-04
EP2210598A3 (de) 2011-07-20
DE60131033D1 (de) 2007-11-29
CA2419285C (en) 2011-08-02
EP1486206B1 (de) 2007-10-17
AU2011202293B2 (en) 2013-01-10
LU91512I2 (fr) 2009-03-16
AU2007202336A1 (en) 2007-06-14
PT1486206E (pt) 2008-01-25
US20020086828A1 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
ATE375793T1 (de) Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen
JP2007530493A5 (de)
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
AR061743A1 (es) Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro
JP2008501760A5 (de)
JP2008501753A5 (de)
IS8058A (is) Sýklísk súlfónamíð til að hamla gamma seytiasa
AR061475A1 (es) Compuestos peptidicos para tratar status epilepticus refractario
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
EA200500583A1 (ru) Ингибиторы белка-регулятора трансмембранной проводимости при муковисцидозе и их применение
DE60237100D1 (de) Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
ATE293972T1 (de) Behandlung von chronischen schmerzen
ATE260655T1 (de) Verwendung von stickstoffhaltigen aromatischen heterozyklusderivaten zur topischen behandlung von epithelerkrankungen
TR200103562T2 (tr) Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE423564T1 (de) Zusammensetzung für die kosmetische behandlung von altersbedingten dermatologischen symptomen
DE60127571D1 (de) Tiagabine zur behandlung von diabetischer neuropathie
ATE288254T1 (de) Methode zur behandlung von schlaganfall
AR050097A1 (es) Uso de compuestos peptidicos para tratar dolor en neuropatia diabetica dolorosa
RU2001122151A (ru) Препарат для лечения острых послеродовых эндометритов у коров и способ его применения
TH48583A (th) สารผสมสำหรับชักนำการเจริญ
TH55743B (th) เกลือมอร์โฟลิโนเบนซามีดชนิดใหม่
TH23898A (th) วิธีการหยุดยั้งการออกฤทธิ์ของ il-6

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1486206

Country of ref document: EP